Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 177Head & Neck 27Gastrointestinal 27Breast 24CNS 21Genitourinary 18Sarcoma 11Other solid neoplasm 8Tumor-Agnostic 6Gynecologic 6Endocrine 4Dermatologic 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 898Cyclophosphamide 893fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 451Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gefitinib × Other hematologic neoplasm × Clear all
NCT00130702 2014-05-01

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Dana-Farber Cancer Institute

Phase 2 Completed
18 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡